Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


VC Roundup: Caribou Completes $30m Non-IPO CRISPR Financing; $205m In Cash For Five Others

Executive Summary

Gene editing is all the rage in biotechnology these days, but Caribou Biosciences Inc. has taken a different path than its CRISPR peers by diversifying beyond therapeutics to agriculture, industrial and applied research. The company also has taken a different financing path – recently closing a $30m Series B venture capital round instead of pursuing an initial public offering.


Related Content

Aptinyx Cashes In Post-Naurex Cache With $65m Series A
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
VCs Raise Cash For New Deals; Five Biotechs Find Funding
J.P. Morgan Notebook Day 3: Regeneron, AstraZeneca CRISPR And Juno
First US product approval for Taiho Oncology
Servier to pay $130m for Taiho's mCRC drug in Europe
Caribou brings in $11m for CRISPR tech
Novartis to use gene editing tool with CAR-T therapies
Longitude beats 'brutal' conditions as new life science fund exceeds target
Longitude gets some latitude in 'brutal' climate as it builds new $375m fund


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts